Gilead Sciences [GILD] vs Bristol-Myers Squibb [BMY] Detailed Stock Comparison
Gilead Sciences
NASDAQ
Loading...
Bristol-Myers Squibb
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Gilead Sciences wins in 10 metrics, Bristol-Myers Squibb wins in 9 metrics, with 0 ties. Gilead Sciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Gilead Sciences | Bristol-Myers Squibb | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 22.21 | 17.70 | Bristol-Myers Squibb |
| Price-to-Book Ratio | 7.11 | 5.54 | Bristol-Myers Squibb |
| Debt-to-Equity Ratio | 127.34 | 291.55 | Gilead Sciences |
| PEG Ratio | 1.02 | -0.77 | Bristol-Myers Squibb |
| EV/EBITDA | 11.49 | 7.01 | Bristol-Myers Squibb |
| Profit Margin (TTM) | 21.87% | 10.58% | Gilead Sciences |
| Operating Margin (TTM) | 39.16% | 33.68% | Gilead Sciences |
| EBITDA Margin (TTM) | 39.16% | 33.68% | Gilead Sciences |
| Return on Equity | 33.40% | 29.32% | Gilead Sciences |
| Return on Assets (TTM) | 12.62% | 8.33% | Gilead Sciences |
| Free Cash Flow (TTM) | $10.31B | $13.94B | Bristol-Myers Squibb |
| Dividend Yield | 3.25% | N/A | N/A |
| 1-Year Return | 30.70% | -15.25% | Gilead Sciences |
| Price-to-Sales Ratio (TTM) | 4.84 | 2.02 | Bristol-Myers Squibb |
| Enterprise Value | $158.54B | $133.98B | Gilead Sciences |
| EV/Revenue Ratio | 5.49 | 2.81 | Bristol-Myers Squibb |
| Gross Profit Margin (TTM) | 78.80% | 72.52% | Gilead Sciences |
| Revenue per Share (TTM) | $23 | $23 | Bristol-Myers Squibb |
| Earnings per Share (Diluted) | $5.07 | $2.68 | Gilead Sciences |
| Beta (Stock Volatility) | 0.38 | 0.34 | Bristol-Myers Squibb |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Gilead Sciences vs Bristol-Myers Squibb Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Gilead Sciences | 1.94% | -0.39% | -1.91% | -0.85% | -1.19% | 20.33% |
| Bristol-Myers Squibb | -0.63% | 5.34% | -3.54% | -3.99% | -23.27% | -19.48% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Gilead Sciences | 30.70% | 71.97% | 73.18% | 9.85% | 508.48% | 830.64% |
| Bristol-Myers Squibb | -15.25% | -34.39% | -26.03% | -25.57% | 68.37% | 98.83% |
News Based Sentiment: Gilead Sciences vs Bristol-Myers Squibb
Gilead Sciences
News based Sentiment: MIXED
October was a largely positive month for Gilead, with strong earnings and analyst upgrades offset by potential drug pricing pressures. The company's significant investments in R&D and manufacturing signal a commitment to long-term growth, but the Biktarvy pricing issue introduces a notable risk factor, creating a mixed overall investment narrative.
Bristol-Myers Squibb
News based Sentiment: POSITIVE
October was a notably positive month for Bristol Myers Squibb, driven by a strong earnings report, a strategic AI partnership, and proactive measures to address drug pricing. These developments, coupled with analyst upgrades and positive insider activity, suggest a strengthening investment case and improved future prospects.
Performance & Financial Health Analysis: Gilead Sciences vs Bristol-Myers Squibb
| Metric | GILD | BMY |
|---|---|---|
| Market Information | ||
| Market Cap | $139.74B | $92.49B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 7,201,150 | 22,418,050 |
| 90 Day Avg. Volume | 6,413,223 | 14,085,313 |
| Last Close | $112.71 | $45.44 |
| 52 Week Range | $83.98 - $121.83 | $42.96 - $63.33 |
| % from 52W High | -7.49% | -28.25% |
| All-Time High | $123.37 (Jun 22, 2015) | $81.44 (Nov 28, 2022) |
| % from All-Time High | -8.64% | -44.20% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.02% | 0.01% |
| Quarterly Earnings Growth | 0.21% | -0.22% |
| Financial Health | ||
| Profit Margin (TTM) | 0.22% | 0.11% |
| Operating Margin (TTM) | 0.39% | 0.34% |
| Return on Equity (TTM) | 0.33% | 0.29% |
| Debt to Equity (MRQ) | 127.34 | 291.55 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $15.84 | $8.57 |
| Cash per Share (MRQ) | $4.88 | $6.68 |
| Operating Cash Flow (TTM) | $9.87B | $15.90B |
| Levered Free Cash Flow (TTM) | $8.84B | $16.19B |
| Dividends | ||
| Last 12-Month Dividend Yield | 3.25% | N/A |
| Last 12-Month Dividend | $3.91 | N/A |
Valuation & Enterprise Metrics Analysis: Gilead Sciences vs Bristol-Myers Squibb
| Metric | GILD | BMY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 22.21 | 17.70 |
| Forward P/E | 15.16 | 6.75 |
| PEG Ratio | 1.02 | -0.77 |
| Price to Sales (TTM) | 4.84 | 2.02 |
| Price to Book (MRQ) | 7.11 | 5.54 |
| Market Capitalization | ||
| Market Capitalization | $139.74B | $92.49B |
| Enterprise Value | $158.54B | $133.98B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.49 | 2.81 |
| Enterprise to EBITDA | 11.49 | 7.01 |
| Risk & Other Metrics | ||
| Beta | 0.38 | 0.34 |
| Book Value per Share (MRQ) | $15.84 | $8.57 |
Financial Statements Comparison: Gilead Sciences vs Bristol-Myers Squibb
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GILD | BMY |
|---|---|---|
| Revenue/Sales | $6.67B | $12.27B |
| Cost of Goods Sold | $1.54B | $3.37B |
| Gross Profit | $5.13B | $8.90B |
| Research & Development | $1.38B | $2.58B |
| Operating Income (EBIT) | $2.49B | $3.77B |
| EBITDA | $3.28B | $5.26B |
| Pre-Tax Income | $1.65B | $1.77B |
| Income Tax | $334.00M | $460.00M |
| Net Income (Profit) | $1.32B | $1.31B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GILD | BMY |
|---|---|---|
| Cash & Equivalents | $7.93B | $10.88B |
| Total Current Assets | $16.90B | $30.78B |
| Total Current Liabilities | $12.34B | $24.07B |
| Long-Term Debt | $22.15B | $47.51B |
| Total Shareholders Equity | $19.08B | $17.45B |
| Retained Earnings | $10.93B | $16.11B |
| Property, Plant & Equipment | $7.96B | $1.22B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GILD | BMY |
|---|---|---|
| Operating Cash Flow | $1.56B | $2.11B |
| Capital Expenditures | $-104.00M | N/A |
| Free Cash Flow | $1.65B | $1.69B |
| Debt Repayment | $-1.76B | N/A |
| Common Stock Repurchase | $-730.00M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GILD | BMY |
|---|---|---|
| Shares Short | 18.25M | 29.47M |
| Short Ratio | 2.97 | 3.05 |
| Short % of Float | 0.01% | 0.01% |
| Average Daily Volume (10 Day) | 7,201,150 | 22,418,050 |
| Average Daily Volume (90 Day) | 6,413,223 | 14,085,313 |
| Shares Outstanding | 1.25B | 2.03B |
| Float Shares | 1.24B | 2.03B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.91% | 0.83% |
Dividend Analysis & Yield Comparison: Gilead Sciences vs Bristol-Myers Squibb
| Metric | GILD | BMY |
|---|---|---|
| Last 12-Month Dividend | $3.91 | N/A |
| Last 12-Month Dividend Yield | 3.25% | N/A |
| 3-Year Avg Annual Dividend | $3.30 | N/A |
| 3-Year Avg Dividend Yield | 0.91% | N/A |
| 3-Year Total Dividends | $9.91 | N/A |
| Ex-Dividend Date | Sep 15, 2025 | N/A |